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Abstract 
Sjögren’s syndrome (SS) is a systemic autoimmune disorder that mainly affects the salivary 
and lacrimal glands, giving rise to clinical symptom such as oral and ocular dryness, 
xerostomia and keratoconjunctivitis sicca, respectively. When the disease occurs alone it is 
termed primary SS, and when in association with a connective tissue disease it is termed 
secondary SS. As of today, SS remains a benign, but non-curable disease. Treatment is mainly 
palliative. With better understanding of the disease pathogenesis, SS may be diagnosed at an 
earlier stage and targeted, interceptive treatment applied. SS may have multiple implications 
on oral health, and quality of life. Ocular manifestations are managed with local stimulation 
of the lacrimal glands, and supportive surgical procedures. Treatment of xerostomia includes 
strict oral hygiene regimes, saliva substitutes, and various agents to stimulate salivary flow. In 
this master thesis, we review the literature on the use of the muscarinic cholinergic agonists 
pilocarpine and cevimeline, which both have been shown to reduce symptoms of oral and 
ocular dryness in patients with SS. 
 
Norwegian summary 
Sjögrens syndrom (SS) er en systemisk autoimmun sykdom som primært påvirker spytt- og 
tårekjertler og gir kliniske symptom som tørrhet i munn (xerostomia) og øyne 
(keratokonjunctivitis sicca). Sykdommen forekommer enten alene å kalles da primær SS, eller 
sammen med en annen bindevevssykdom og kalles da sekundær SS. Per i dag finnes det ingen 
kur for å stanse utviklingen av SS, og behandlingen retter seg fremst mot å dempe 
symptomer. Ved bedre forståelse av sykdomsutviklingen kan sykdommen diagnostiseres 
tidligere, og målrettet forebyggende behandling tillempes. SS har flere konsekvenser for oral 
helse, og livskvalitet. Øye manifestasjoner behandles med lokal stimulering av tårekjertlene, 
og kirurgiske inngrep. Behandling av xerostomia inkluderer god oral hygiene, bruk av saliv 
erstatning, og stimulering av salivsekresjon på forskjellige måter. Denne prosjektoppgaven 
omhandler bruk av muscarine cholinerg agonistene pilocarpin og cevimelin, som begge har 
vist å kunne bedre symptom på munn- og øyetørrhet hos pasienter med SS. 
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Introduction 
Sjögren’s syndrome (SS) is an autoimmune, chronic inflammatory disease characterized by 
progressive focal mononuclear cell infiltration of exocrine glands, primarily the lacrimal and 
salivary glands. The lymphoid infiltrations are associated with clinical symptoms such as 
dryness of the mouth (xerostomia) and eyes (keratokonjunctivits sicca). Dryness of the nose, 
throat, vagina and skin has also been described. The peak incidence of the disease is in the 
fourth and fifth decade of life, with a female: male ratio of 9:1 (1). 
The disease is named after the Swedish ophthalmologist Henrik Sjögren (1899 -1986) who in 
his doctoral dissertation in 1933 reported the detailed clinical and histopathological findings 
of 19 women with xerostomia and keratoconjunctivitis sicca, of whom 13 had chronic arthritis 
(2). 
SS may occur as an isolated phenomenon with the clinical manifestations of xerostomia and 
keratokonjunctivits sicca, focal sialadenosis and/or serum auto antibodies. It is then termed 
primary Sjögren’s syndrome (pSS). In cases where sicca symptoms occur in association with 
connective tissue disorders, the most frequent being rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) or scleroderma, the disease is referred  to as secondary Sjögren’s 
syndrome (sSS) (1). Dry mouth and dry eyes are the most common subjective complaints of 
patients suffering from SS, and deviations in the quality and quantity of saliva may have a 
negative impact on dental and oral health. A predominant characteristic of patients with SS is 
reduced salivary flow rates of resting whole, and parotid saliva (3). 
Increased incidence of cervical and root caries, oral candidiasis, mucositis (Table 1) and 
swelling of the salivary glands are frequent oral signs of SS. In addition to general discomfort, 
the lack of saliva may be accompanied by glossitis, angular cheilitis, problems in swallowing 
(dysphagia) and speaking, and alterations in taste (Table 1) (1, 4). 
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Table 1. Approximate frequency of oro-pharyngeal clinical manifestations in patients with 
Sjögren’s syndrome. Adapted from Rhodus, 1999 (4). 
Clinical manifestation Prevalence % 
Angular cheilitis 88 
Glossitis 90 
Mucositis 30 
Glossodynia 45 
Dysgeusia 75 
Dysphagia 55 
Candidiasis 83 
Dental caries 100 
Periodontitis 80 
 
In comparison to other, more severe autoimmune diseases, symptoms of SS can seem minor. 
However, the complexity of symptoms and the chronicity of the disease will not only affect 
patient’s quality of life but may also lead to significant morbidity and mortality owing to an 
increased risk of malignant transformation (5, 6). 
 
Etiology and disease mechanisms of Sjögren’s syndrome 
SS is a complex disorder of unknown etiology. The susceptibility of disease can better be 
explained by an interplay between the environment and genetic factors (1), where an 
unknown environmental stimulus e.g., viral infections, may trigger SS in genetically 
predisposed individuals (Figure 1). Potential viral triggers includes Epstein-Barr virus (EBV), 
hepatitis C virus (HCV), and human T-cell leukemia virus (HTLV-1) (1). Albeit the level of 
genetic contribution is still far from being understood, findings in animal studies, candidate 
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gene association studies, and family aggregation studies confirm a genetic predisposition in 
the pathogenesis of SS (7). 
 
 
Figure 1. Possible events in the initiation and progression of disease in Sjögren’s syndrome. 
Adapted from Jonsson et al 2005 (1). 
 
In a very general way, the sicca symptoms in SS are attributed to lymphocytic infiltration of 
the glandular tissues, where the deficient secretory response of the salivary and lacrimal 
glands are thought to occur as a consequence of immune-cell mediated destruction of 
glandular tissues, eventually leading to the symptoms of dryness. However, processes 
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triggering lymphocyte recruitment into the exocrine glands, and the exact function of the cells 
while within the glands, are still a matter of speculation.  
Recently, understanding of the pathology underlying glandular hypofunction has undergone a 
dramatic change. Firstly, many patients with SS have within their salivary glands large 
amounts of acinar tissue that is unable to function in vivo. Secondly, data from work on 
salivary acinar cells isolated from patients with SS demonstrates a reduced sensitivity to 
threshold levels of muscarinic stimulation, although the remaining tissue is functional in vitro. 
Overall, these findings suggest that the lack of glandular function in many patients with SS is 
the result of a perturbation of acinar function, ultimately followed by atrophy (8). 
 
Diagnosis and management of Sjögren’s syndrome 
The diagnosis of SS should be based on several clinical and laboratory findings. The items 
classifying the oral component are based on the presence of subjective or objective oral 
dryness, and are usually considered cardinal features of SS. Over the years, different sets of 
classification criteria have been suggested for the diagnosis of SS. Among these are the 
Copenhagen criteria, the Californian criteria, the Greek criteria and the Japanese criteria (9). 
On the basis of latest data, a modified classification criteria (Table 2) set new rules for the 
correct classification of patients with pSS and sSS, and a list of exclusion criteria (Table 3) 
were drafted and approved by all the American-European Consensus group. Presently, the 
modified criteria most likely represent the best instrument available for the correct 
classification of SS. 
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Table 2. Revised American-European classification criteria for Sjögren’s syndrome. Adapted 
from Vitali et al, 2002 (9). 
 
I. Ocular symptoms (at least one of the following) 
- Daily, persistent, troublesome dry eyes for more than 3 months. 
- Recurrent sensation of sand or gravel in the eyes. 
- Use of a tear substitute more than 3 times/day. 
 
II. Oral symptoms (at least one of the following) 
- Daily feeling of dry mouth for at least 3 months. 
- Recurrent feeling of swollen salivary glands as an adult. 
- Drinking liquids to help to wash down dry foods. 
 
III. Objective evidence of dry eyes (at least one of the following) 
- Schirmer’s I test: 5 mm or below/5 minutes.  
- Rose-Bengal score of 4 or greater according to the van Bijsterveld system. 
 
IV. Histopathologic signs 
- Minor salivary gland biopsy with focus score of 1 or greater. 
 
V. Objective evidence of salivary gland involvement (at least one of the following) 
- Salivary gland scintigrahy showing delayed uptake, reduced concentration and/or delayed excretion of tracer. 
- Parotid scintigrahy showing the presence of diffuse sialectasias, without evidence of obstruction in the major 
ducts. 
- Un-stimulated whole sialometry less than 1.5 ml/15 minutes. 
 
VI. Laboratory abnormality (presence in the serum of the following auto antibodies) 
- Antibodies to Ro/SSA or La/SSB antigens, or both.   
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Table 3. Revised rules for the classification of SS. Adapted from Vitali et al, 2002 (9). 
For primary SS: 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(histopathology) or VI (serology) is positive  
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V and VI) 
c. The classification tree procedure  is a valid alternative method for classification , although it should be 
more properly used in clinical-epidemiology survey 
 
For secondary SS:  
In patients with a potentially associated disease (for instance, another well defined connective tissue disease), the 
presence of item I or item II plus any 2 from among items III, IV and V, may be considered as indicative of 
secondary SS. 
 
Exclusion criteria: 
• Past head and neck radiation therapy 
• Hepatitis C infection  
• Acquired immunodeficiency syndrome 
• Sarcoidosis 
• Graft-versus-host disease  
• Use of anticholinergic drugs (since a time shorter than 4-fold life of the drug) 
 
 
 Despite advances in the understanding of disease pathogenesis and clinical manifestations, 
physicians and dentist have long felt discouraged in the care of patients with SS. Current 
treatment of SS includes palliative treatment to manage dryness, stimulation of salivary gland 
function, treatment of systemic autoimmune features (Table 4), and management of non-
specific symptoms such as fatigue (10). In the light of SS being an autoimmune disease, 
initial approaches were to treat the disease by immunomodulating drugs (Table 4) to alleviate 
the dry mouth and dry eyes symptoms. However, these drugs are usually reserved for severe 
cases of SS, involving extra-glandular manifestations or severe fatigue. Investigations looking 
solely into the treatment of dry mouth or eye symptoms using these agents are sparse (11, 12). 
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Table 4. Potential immunomodulating agents for the treatment of Sjögren’s syndrome. 
Adapted from Mavragani et al, 2006 (3). 
Agent Formulation and dose Outcome Reference 
Cyclosporine 5 mg/kg body weight daily 
Improvement of subjective 
measures of xerostomia. 
No improvement of 
objective indices. 
(3) 
Methotrexate 0.2 mg/kg body weight weekly 
Improvement in subjective 
measures. 
No improvement of 
objective indices. 
(3) 
Azathriopine 1 mg/kg body weight daily No improvement detected. Adverse effects. (3) 
Corticosteroids Systemic 0.5-1.0 mg/kg body weight daily 
Limited evidence of 
improvement.              (3) 
Hydroxychloroquinone 200 mg daily No improvements in sicca symptoms. 
 
             (3) 
Interferon-alpha 150 IU 3 times daily for 24 weeks (oromucosal route) 
Improvement in oral and 
ocular symptoms, increase 
in un-stimulated whole 
salivary flow. 
(13) 
Nucleoside analogs Zidovudine 250 mg twice daily 
Significant improvement 
in sicca symptoms and 
objective measures. 
             (3) 
 
 
Aims of the project 
This study was undertaken with the general aim of reviewing the literature on the 
management of Sjögren’s syndrome. The specific aims were to evaluate the therapeutic value 
of muscarinic agonists for the relief of symptoms of dry mouth, and to illustrate the clinical 
outcome of pilocarpine and cevimeline in stimulating salivary flow, as an effective long-term 
therapy for patients with SS. 
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Muscarinic receptors in Sjögren’s syndrome 
 Acetylcholine (ACh) is a neurotransmitter mediating physiologic responses such as smooth 
muscle contraction, glandular secretion and cardiac rate, through a family of muscarinic 
acetylcholine receptors (mACR). The muscarinic receptor family is encoded by five 
muscarinic gene products designated M1 through M5 (14). In SS, the expression of mACR of 
the M1 and M3 subtypes in lacrimal and salivary glands is of particular interest (15). 
Interestingly, an increase in acinar cell expression of (M3R) muscarinic type 3 receptors has 
been demonstrated (16). Such an increase in M3R would be expected to result in acinar cell 
hyperfunction, a phenomenon that has been observed in the early stage of disease and in a 
very small number of patients (17). However, although the number of M3Rs in the salivary 
glands of patients with SS are increased, they were found to be hypo functional (14). 
The understanding of the salivary gland dysfunction associated with SS, as well as the 
detection of antibodies that could precipitate muscarinic receptors with an antimuscarinic 
antibody activity has long been a matter of discussion. Recently, findings in non-obese 
diabetic (NOD) mice, an animal model of SS, could establish that M3Rs indeed are involved 
in the pathology responsible for salivary gland dysfunction (8).  
In recent years, the development of sialologogues, i.e. an agent that stimulates salivary flow, 
have received interest for the treatment of SS (10). The use of muscarinic agonists such as 
pilocarpine or cevimeline which act through stimulation of M3 and M1 receptors, and its 
value as therapeutic option for the relief of dry mouth and dry eyes in patients with SS will be 
presented below. 
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Muscarinic agonist for treatment of Sjögren’s syndrome 
Pilocarpine 
Pilocarpine is a natural tertiary alkaloid derived from the leaves of a bush in South America, 
called Pilocarpus jaborandi (Figure 2). The word jaborandi actually means “the slobber 
mouth plant”, and Brazilian native Tupi Indians have for centuries known that chewing on the 
leaves of Pilocarpus jaborandi will stimulate salivary flow (12). 
 
 
Figure 2. Chemical structure of pilocarpine. Adapted from Fox et al 2001 (14). 
 
Absorption of pilocarpine from the gastrointestinal tract is rapid, and produces both a central 
and a peripheral muscarinic effect within 20 minutes of ingestion (14). Pilocarpine acts as a 
direct muscarinic agonist with activity at all muscarinic receptors (M1-M5). Metabolism 
mainly occurs in the liver, but approximately 20% is excreted unchanged in the urine, with an 
elimination half-life of approximately 0.76-1.3 hours (18). 
Data from animal models suggest that regular use of pilocarpine may not only improve patient 
quality of life but potentially prevent complications such as caries and candidiasis. A study 
examined the effect of pilocarpine on caries using a model of partially desalivated rats (19). 
The animals’ major salivary glands were surgically altered. They were then inoculated with 
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Streptococcus sobrinus, fed a diet that was over 50% sugar and allowed to drink water with 
10% sugar. The group that had both submandibular and sublingual glands excised but were 
treated with pilocarpine, had a significantly reduced incidence of caries compared to partially 
desalivated, untreated controls, suggesting that at least in rats with dry mouth, administration 
of pilocarpine could be issued to prevent caries (19). These findings were confirmed in a 
second study where stimulation of saliva by pilocarpine treatment was able to reverse 
sucrose-induced fissure caries in albino rats (20). 
In humans, pilocarpine has previously been used in ophthalmic preparations for the treatment 
of glaucoma, but the efficiency of pilocarpine in stimulating salivary flow as a long-term 
therapy for patients with primary and secondary SS has been confirmed in several studies, 
reviewed in (3, 21). Subjective and objective benefits of pilocarpine have also been shown in 
patients with radiation-induced xerostomia, a state similar to salivary changes in patients with 
SS (22). 
Many studies have addressed the question of the optimal dosage of pilocarpine (Table 5). To 
investigate the efficacy and safety of pilocarpine, a prospective, randomized, double-blind, 
placebo-controlled trial was undertaken in 207 patients who received more than 40 Gy of 
radiation to the head and neck (23). The patients were given pilocarpine (5.0 mg or 10.0 mg 
orally three times a day) or placebo for 12 weeks, and were evaluated at baseline and every 4 
weeks. In the patients receiving the 5 mg dose of pilocarpine oral dryness improved in 44 
percent as compared with 25 percent of the patients receiving placebo. Overall improvement 
was achieved in 54 percent of the 5.0 mg group as compared with 25 percent of the placebo 
group, with a general increase in saliva production, as well as improved speaking, swallowing 
and chewing ability. Side effects were predominantly limited to sweating (23). 
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Most long-term studies report of doses 5.0 mg three times daily. Lower doses such as 2.5 mg 
three times daily did not seem to have an effect (18, 24), but neither did higher doses, such as 
10.0 mg three times daily. Instead, higher doses were associated with more side effects, 
primarily increased sweating and drug intolerance (22, 23). Reports from a multicenter, 
placebo-controlled study in patients with SS indicated a significant increase in salivary 
secretion rate following pilocarpine administration, suggesting that the optimal dose of oral 
pilocarpine is 5.0 mg four times daily (25). Such as dosage was associated with marked 
clinical improvement and the lowest incidence of adverse effects (26). 
 
Table 5. A summary of clinical studies evaluating the use of pilocarpine. 
Etiology of xerostomia Patients (n) Controls (n) Pilocarpine (dosage) Outcome Reference(s) 
Diagnosis of SS 
(primary and secondary) 18 9 
2% mg liquid 
ophthalmic drop 
preparation, 4 drops 3 
times a day 
Significant overall 
increase in parotid 
stimulated  and whole un-
stimulated salivary flow 
(27) 
Post-irradiation 
xerostomia in patients 
with head and neck 
cancer 
207 
5 mg (n=73) 
10 mg 
(n=69) 
5 mg tablets placebo or 
10 mg pilocarpine 3 
times a day 
Improved saliva 
production and relieved 
symptoms of xerostomia 
(23) 
Radiation-induced 
xerostomia in patients 
with head and neck 
cancer 
369 207 
2.5 mg tablets first 4 
weeks, 5.0 mg the next 
4 weeks and 10 mg the 
last 4 weeks, three times 
a day 
Significant clinical 
benefits; 
improvement in oral 
dryness, ability to speak, 
and mouth comfort   
(22) 
Diagnosis of SS 
(primary and secondary) 18 9 
5.0 mg tablets single 
dose 
Significant increase in 
labial salivary flow and 
whole salivary flow 
(28) 
SS 256 128 
5.0 mg 4 times daily 
with escalation dose of 
7.5 mg 4 times a day, 6 
weeks after initiation of 
treatment 
Significant relief of dry 
mouth symptoms at 20 
mg/day, and ocular 
symptoms at 30 mg/day 
(16) 
Primary SS 60 46 5.0 mg in a 5% solution sublingually  
Significant increase in 
stimulated salivary flow (29) 
Healthy subjects 40 10 
10 ml. 0.5, 1 and 2% 
topical pilocarpine 
solution 
Increase in salivary flow (30, 31) 
Xerostomia associated 
with radiotherapy, SS, 
sialadenosis, and 
xerogenic administration 
45 - 5 mg tablets daily Elevated salivary flow rate (31) 
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To compare short-term effects of a single oral administration of 5.0 mg of pilocarpine on the 
salivary flow rate was measured in a mixed cohort study of 45 patients suffering from 
xerostomia due to radiotherapy, SS, sialadenosis, and medication. The best results were 
observed in the sialadenosis group followed by the patients with SS. The radiotherapy group 
experienced a slight increase in salivary secretion rate. Side effects were mild and did not 
affect compliance, highlighting the beneficial potential of the use of pilocarpine (22). 
Long-term effects of pilocarpine were investigated in a single-blind, placebo-controlled study 
performed on 18 patients with SS. Nine patients received pilocarpine, and nine received 
placebo. Salivary stimulation was also compared between patients with pSS and sSS. In 
contrast to other studies, four drops of a liquid ophthalmic solution of 2% pilocarpine was 
applied orally three times a day for 6 weeks, the dosage being equivalent to previously 
described 5 mg 3 times a day. The results indicated a significant overall increase in both 
whole un-stimulated and parotid stimulated salivary flow in the pilocarpine group as 
compared with the placebo group. Two of nine patients experienced adverse effects, one 
being slight burning of the oral mucosa shortly after the initial administration of the drug, and 
the other a slightly increased diaphoresis. Concerning dosage, the results from this study 
support the therapeutic dose of 5.0 mg three times daily, suggesting pilocarpine as a safe, 
effective and available treatment for the stimulation of salivary flow in patients with SS (27). 
A similar study investigated the salivary function in 60 patients with primary SS, by 
measuring un-stimulated basal salivary flow and stimulated salivary flow using a single dose 
of 5 mg of pilocarpine in a 5% liquid ophthalmic, administered sublingually. A significant 
increase in stimulated salivary flow was observed in comparison to anethole trithione (ANTT) 
stimulated salivary flow. Twenty-two of the 46 patients with low un-stimulated salivary flow 
had stimulation over 1.5 ml. Thus, pilocarpine even stimulated the residual function with an 
overall improvement in xerostomia perceived as better oral moisture and lubrication. In the 
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study, adverse appeared to be negligible; 2/46 (4%) patients experienced minor side effects, 
and respiratory or cardiovascular disease were not observed (29). 
To determine whether treatment with pilocarpine tablets could alter chronic tongue and mouth 
burning symptoms related to oral candidiasis, twelve patients with this complication were 
investigated. Patients were given 5 mg pilocarpine tablets three times a day for twelve 
months. Salivary flow rates improved with the use of pilocarpine, and colony counts of 
Candida albicans were significantly reduced compared to baseline. The study concluded that 
in addition to using antifungal medications, a secretagogue may be useful for treatment of 
prevention of recurrent oral candidiasis and burning mouth syndrome in SS (32). 
Due to different paths of progression in different patients and at different rates, the duration of 
symptoms as a predictor of response to therapy is insufficient. Histology is not always a 
useful predictor of response because neural dysfunction along with parenchymal damage also 
contributes to the pathogenesis of hyposalivation in SS. Salivary scintigrahy can also be used 
to determine the severity of glandular involvement, as well as the patients ability to form 
saliva (1). 
Compared to other medications used in the treatment of SS (Table 4) pilocarpine can be 
considered a relatively safe drug with few severe side-effects. Adverse effects are primarily 
associated with the cholinergic activity of the drug and may include chills, dizziness, hyper 
salivation, flushing, increased lacrimation, sweating, heart palpitations, and gastrointestinal 
tract disturbance. Mild and tolerable side-effects are frequently reported during pilocarpine 
therapy, their incidence being dose-related. Sweating is reported as the most common adverse 
effect, reviewed in (12). 
Pilocarpine is contraindicated in patients with uncontrolled asthma and obstructive pulmonary 
disease, as it may increase airway resistance, as well as muscle contraction and bronchial 
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secretion. Due to the possibility of cardiac disturbances, caution should also be applied in 
patients with cardiovascular disease and patients taking beta-adrenergic antagonists (24). 
In general, it seems that the effects of pilocarpine treatment are restricted to ongoing therapy. 
If treatment is discontinued, symptoms will go back to baseline. Interestingly, both subjective 
and objective improvements are observed after some months of using pilocarpine, indicating 
that at least two to three months may be necessary to allow the medication to work (3, 26, 31). 
In cases where disease symptoms increase worse over time, it is suggested that it is the natural 
progression of the disease, not the pilocarpine losing effect (21). 
  
Cevimeline 
Originally described in the neuroscience literature as AF102B (Figure 3) cevimeline is a 
structurally rigid analog of acetylcholine that binds to muscarinic acetylcholine receptors with 
a relatively high specificity for muscarinic M1 and M3 receptors. Cevimeline shows a 40-fold 
greater relative affinity for the M3 receptor than for the M2 cardiac receptor compared with 
pilocarpine as well as long-lasting sialogogic action. In addition, the half- life of cevimeline in 
serum is longer than that of pilocarpine (15). 
In preliminary studies on rodents and canines, administration of cevimeline significantly 
increased the volume of saliva excreted from the major salivary glands (33). Results from a 
double-blind, randomized, placebo-controlled study supported the therapeutic value of 
cevimeline for increasing lacrimal and salivary flow (34). A double-blind, randomized, 
placebo-controlled, multi-center trial enrolled seventy-five patients with SS and associated 
salivary gland dysfunction. Study participants were randomized to receive 30 mg or 60 mg of 
cevimeline or placebo, three times daily for six weeks. Regarding dosage,  results supported 
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previous findings, where 30 mg of cevimeline three times daily seemed better tolerated and 
provided substantial relief of xerostomia as compared with the 60 mg therapy of cevimeline, 
which was associated with an increased occurrence in adverse effects, particularly 
gastrointestinal tract disorders (35). 
 
 
Figure 3. Chemical structure of cevimeline. Adapted from Fox et al 2001 (14). 
 
Encouraged by success of early studies, the effects of cevimeline on various components in 
human saliva, such as immunoglobulin A (IgA), lysozyme and alpha amylase, were 
investigated in twelve patients with SS and fourteen healthy controls. The study demonstrated 
that cevimeline not only promoted salivary flow rate, but also increased the secretion of the 
previously mentioned salivary components. Thus, in order to prevent oral infections and other 
serious sequelae, the use of cevimeline may prove beneficial for patients with SS (36). 
A recent study evaluated the effects of cevimeline on health-related quality of life and oral 
health status. The study was a randomized, double-blind, placebo-controlled crossover study.  
Patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks, 
followed by a 4-week washout period, before treatment crossover. Patients were also asked to 
complete a set of questionnaires. Clinical assessments included sialometry, an intra-oral 
examination to determine the degree of xerostomia, hyposalivation-induced dental 
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complications. Results indicated a significant improvement in subjective xerostomia and 
general oral health following treatment with cevimeline. However, no improvement was 
observed in salivary flow rates or dry eye symptoms (37). 
 
Table 6. A summary of clinical studies evaluating the use of cevimeline. 
Etiology of 
xerostomia 
Patients 
(n) 
Controls 
(n) 
Cevimeline 
(dosage) Outcome Reference 
SS and associated 
salivary gland 
dysfunction 
75 23 
30 mg tablets 3 
times daily, 60 mg 
3 times daily or 
placebo 
Cevimeline 30 mg 3 
times daily gives 
substantial relief of 
xerostomia 
(35) 
SS patients with 
xerostomia and 
keratokonjunctivits 
sicca 
197 70 
Either placebo or 
15 mg tablets 3 
times a day or 30 
mg 3 times a day 
30 mg cevimeline 3 
times a day gave 
substantive improvement  
in salivary and tear flow 
(34) 
SS (primary and 
secondary) 60 20 
Either placebo or 
cevimeline 20 mg 
tablets 3 times a 
day or 30 mg 3 
times a day 
Statistically significant 
differences with 20 mg 
cevimeline 
(38) 
SS (primary and 
secondary) 12 14 
30 mg capsule 
single dose 
Promotion of salivary 
flow rate and increased 
secretion of salivary 
components 
(36) 
pSS (n=22) 
sSS (n=28) 50 23 
30 mg tablet or 
placebo 3 times a 
day 
General improvement in 
XI and GOHAI index (37) 
XI – xerostomia index; GOHAI – general oral health index 
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Conclusions 
Salivary substitutes and oral moisturizers are the primary choices in initial, local treatment of 
xerostomia, but due to their minimal longevity and retentiveness, their effect is limited in 
patients with more than mild to moderate symptoms (10). Alternatively, saliva substitutes do 
not help, or are not tolerated (12). In these cases, pilocarpine and cevimeline may prove more 
effective in improving hyposalivation and xerostomia. 
Pilocarpine has been approved in many countries including the USA and Sweden, but not in 
Norway. Nonetheless, in cases where pilocarpine is indicated, it may be ordered from Sweden 
under the registered name of Salagen® after applying for exemption from registration (39). In 
the United States cevimeline is registered under the name of Evoxac®, but due to lack of 
documentation proving safety and efficacy, the European drug authorities rejected the 
registration of cevimeline in 2001. Hence, to alleviate subjective and objective symptoms of 
xerostomia and hyposalivation in Scandinavian patients, pilocarpine will be the drug of 
choice for stimulating salivary flow. 
Direct clinical comparisons in double-blind studies of pilocarpine and cevimeline in patients 
with SS are not yet available. However, data  from pharmacological studies suggest that 
cevimeline has a longer plasma half-life than pilocarpine (14, 15). Moreover, a relative 
increase in specificity for binding to M3R and a decreased binding to M2 receptors, 
pilocarpine potentially gives more serious adverse effects due to cardiac tissue stimulation, in 
theory suggesting a benefit of cevimeline.  
The recommended dosage of oral pilocarpine with minimal side effects is 5 mg four times a 
day (total 20 mg/day). However, an initial dosage of 2.5 to 5.0 mg three times daily (up to 30 
mg/day) at variable dosage intervals may be considered for patients who have not responded 
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adequately with the 20 mg/day dosage. The management recommendation of cevimeline is 30 
mg, given 3 times a day orally for the relief of hyposalivation and xerostomia in SS. 
The primary endpoint for the therapeutic efficacy is increased salivary flow, which is not 
necessarily accompanied by symptomatic improvement. It may require up to 4 weeks for the 
peak effects of pilocarpine on salivary flow to be evident. Careful and frequent follow-up 
evaluations (6 to 8 weeks) are important to asses these parameters as well as to determine 
adverse effects and adjust dosage quantities and intervals. Pilocarpine may be administered 
indefinitely, as long as the salivary flow continues to be stimulated and the patient does not 
suffer severe side effects. Moreover, pilocarpine may be discontinued immediately and 
completely without adverse effects. 
 
 21 
References 
  
1. Jonsson R, Bowman SJ, Gordon TP. Sjögren's syndrome. In: Koopman WJ, editor. 
Arthritis and allied conditions. 15th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. 
p. 1681-1705. 
2. Mutlu S, Scully C. The person behind the eponym: Henrik Sjögren (1899-1986). J 
Oral Pathol Med. 1993;22(10):439. 
3. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's 
syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252-261. 
4. Rhodus NL. Sjögren's syndrome. Quintessence Int. 1999;30(10):689-699. 
5. Theander E, Andersson SI, Manthorpe R, Jacobsson LT. Proposed core set of outcome 
measures in patients with primary Sjögren's syndrome: 5 year follow up. J Rheumatol. 
2005;32(8):1495-1502. 
6. Theander E, Henrickson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. 
Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer 
incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796-783. 
7. Bolstad AI, Haga HJ, Wassmuth R, Jonsson R. Monozygotic twins with primary 
Sjögren's syndrome. J Rheumatol. 2000;27(9):2264-2266. 
8. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's 
syndrome: where are we, and where are we going? Arthritis Rheum. 2005;52(10):2984-2995. 
9. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et 
al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria 
proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-
558. 
10. von Bultzingslöwen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, et al. 
Salivary dysfunction associated with systemic diseases: systematic review and clinical 
management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2007;103 Suppl:S57 e1-15. 
11. al-Hashimi I, Taylor SE. A new medication for treatment of dry mouth in Sjögren's 
syndrome. Tex Dent J. 2001;118(3):262-266. 
12. Fox RI, Michelson P. Approaches to the treatment of Sjögren's syndrome. J 
Rheumatol Suppl. 2000;61:15-21. 
13. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's 
syndrome with low-dose human interferon alfa administered by the oromucosal route: 
combined phase III results. Arthritis Rheum. 2003;49(4):585-593. 
14. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of 
Sjögren's syndrome. Clin Immunol. 2001;101(3):249-263. 
15. Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of 
Sjögren's syndrome. Adv Exp Med Biol. 2002;506(Pt B):1107-1116. 
16. Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA, Jr., Walsh BT, et al. 
Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients 
With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin 
Rheumatol. 2004;10(4):169-177. 
17. Haga H-J, Jonsson R. The Influence of Age on Disease Manifestations and Serological 
Characteristics in Primary Sjögren's Syndrome. Scandinavian Journal of Rheumatology. 
1999;28(4):227 - 232. 
18. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, 3rd, Tran-Johnson TK, 
et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with 
 22 
Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 
Study Group. Arch Intern Med. 1999;159(2):174-181. 
19. O'Connell AC, Pearson SK, Bowen WH. Pilocarpine alters caries development in 
partially-desalivated rats. J Dent Res. 1994;73(3):637-643. 
20. Leach SA, Connell R. Reversal of fissure caries in the albino rat by stimulating 
salivary flow with pilocarpine. Caries Res. 1990;24(2):127-129. 
21. Vivino FB. The treatment of Sjögren's syndrome patients with pilocarpine-tablets. 
Scand J Rheumatol Suppl. 2001(115):1-9; discussion 9-13. 
22. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, et al. 
Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from 
two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys. 1995;31(3):661-669. 
23. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral 
pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J 
Med. 1993;329(6):390-395. 
24. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties 
and clinical potential in xerostomia. Drugs. 1995;49(1):143-155. 
25. Papas A, Charney M, Golden H, Medsger T, Sherrer Y, Walsh B et al. The 
effectiveness of oral pilocarpine HCL tablets for the treatment of dry mouth symptoms 
associated with Sjögren's syndrome: a dose titration study. Arthritis Rheum. 1997;40(9). 
26. Vivino F LVF, Khan Z, Salisbury P,Tran-johnsonT, Trivedil M, et al. Long term 
safety of pilocarpine tablets following chronic administration to patients with Sjögren's 
syndrome for the relief of symptoms of dry mouth and dry eyes. Arthritis Reum. 1998;41(9). 
27. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with 
Sjögren's syndrome. Oral Surg Oral Med Oral Pathol. 1991;72(5):545-549. 
28. Rhodus NL. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in 
patients with Sjögren's syndrome. Oral Dis. 1997;3(2):93-98. 
29. Rosas J, Ramos-Casals M, Ena J, Garcia-Carrasco M, Verdu J, Cervera R, et al. 
Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. 
Correlation with clinical, immunological and histological features. Rheumatology (Oxford). 
2002;41(6):670-675. 
30. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR, et al. Effect of 
pilocarpine mouthwash on salivary flow. Braz J Med Biol Res. 2002;35(1):105-110. 
31. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine 
treatment in a mixed cohort of xerostomic patients. Oral Dis. 2007;13(1):88-92. 
32. Rhodus NL, Liljemark W, Bloomquist C, Bereuter J. Candida albicans levels in 
patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: 
a pilot study. Quintessence Int. 1998;29(11):705-710. 
33. Masunaga H, Ogawa H, Uematsu Y, Tomizuka T, Yasuda H, Takeshita Y. Long-
lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. 
Eur J Pharmacol. 1997;339(1):1-9. 
34. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, 
randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with 
xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748-754. 
35. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. 
Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized 
trial. Arch Intern Med. 2002;162(11):1293-1300. 
36. Suzuki K, Matsumoto M, Nakashima M, Takada K, Nakanishi T, Okada M, et al. 
Effect of cevimeline on salivary components in patients with Sjögren syndrome. 
Pharmacology. 2005;74(2):100-105. 
 23 
37. Leung KC, McMillan AS, Wong MC, Leung WK, Mok MY, Lau CS. The efficacy of 
cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern 
Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin 
Rheumatol. 2007. 
38. Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, et al. Therapeutic 
effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-
blind clinical study. Am J Ophthalmol. 2004;138(1):6-17. 
39. www.relis.no/database. Pilocarpin ved Sjögren's syndrome. 2007 14.03.2007:2. 
 
 
